|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 异环磷酰胺、表阿霉素和顺铂对晚期非小细胞肺癌的联合化疗显示文摘48例晚期非小细胞肺癌病人接受了异环磷酰胺加表阿霉素加顺铂(IEP)联合化疗方案。其中40例能评价疗效,包括Ⅳ期17例、Ⅲb期16例、Ⅲa期5例及Ⅱ期2例。部分缓解18例(45%),微小缓解(MR)或无变化(NC)9例(22.5%),无效(NR)13例。有效病例的生存期为5^+—19^+个月(中位时间12.4月)。MR和NC及NR病人的中位生存期为8.8月。所有病人在化疗后都有轻度到中度的恶心、呕吐。30%病例发生Ⅰ级和Ⅱ级白细胞减少,3例发生Ⅲ级白细胞减少,3例发生Ⅱ级和Ⅲ级血小板减少,25%病例有轻度(Ⅱ级)贫血。总之,IEP方案耐受性好,对非小细胞肺癌化疗有效。 | Sumitra Thongprasert Kriengsak Jiemsripongse Chaicharn Phothiratana Budsaba Atikachai 吴海鹰 | 1992 | 癌症1992，11，3： | 13 |
| 2 | Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia显示文摘 | Shukui Qin Yuxian Bai Ho Yeong Lim Sumitra Thongprasert Yee Chao Jia Fan Tsai-Shen Yang Vajarabhongsa Bhudhisawasdi Won Ki Kang Yu Zhou Jee Hyun Lee Yan Sun | 2013 | Journal of Clinical Oncology2013，，28： | 5 |
| 3 | Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma显示文摘AIM: To study the activity of gemcitabine and cisplatin in a cohort of patients with inoperable or metastatic cholangiocarcinoma. METHODS: Chemotherapy-naive patients with pathologically proven cholangiocarcinoma,receiving treatment that consisted of gemcitabine at 1250 mg/m2 in a 30-min infusion on d 1 and 8,and cisplatin at 75 mg/m2 at every 21-d cycle,were retrospectively analyzed. RESULTS: From June 2003 to December 2005,42 patients were evaluated. Twelve patients (28%) had unresectable disease and 30 (72%) had metastatic disease. There were 28 males and 14 females with a median age of 51 years (range 33-67) and median ECOG PS of 1 (range 0-2). A total of 171 cycles were given with a median number of cycles of 4 (range 1-6). There were 0 CR,9 PR,11 SD and 13 PD (response rate 21%). Grade 3-4 hematologic toxicities were: anemia in 33%,neutropenia in 22% and thrombocytopenia in 5%. Non-hematologic toxicity was generally mild. No cases of febrile neutropenia or treatment-related death were noted. The median survival was 10.8 mo (range 8.4-13 mo) and progression free survival was 8.5 mo. One-year survival rate was 40%. CONCLUSION: Our results indicate that the combination of gemcitabine and cisplatin had consistent efficacy in patients with unresectable or metastatic cholangiocarcinoma. | Chaiyut Charoentum Sumitra Thongprasert Busyamas Chewaskulyong Sutthirak Munprakan | 2007 | World Journal of Gastroenterology2007，13，20： | 5 |
| 4 | Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia显示文摘 | Shukui Qin Yuxian Bai Ho Yeong Lim Sumitra Thongprasert Yee Chao Jia Fan Tsai-Shen Yang Vajarabhongsa Bhudhisawasdi Won Ki Kang Yu Zhou Jee Hyun Lee Yan Sun | 2013 | Journal of Clinical Oncology2013，，28： | 2 |
| 5 | A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study显示文摘 | Jun Ho Yi Sumitra Thongprasert Jeeyun Lee D.C. Doval Se Hoon Park Joon Oh Park Young Suk Park Won Ki Kang Ho Yeong Lim | 2011 | European Journal of Cancer2011，，2： | 2 |
| 6 | A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)显示文摘 | Yuankai Shi Joseph Siu-Kie Au Sumitra Thongprasert Sankar Srinivasan Chun-Ming Tsai Mai Trong Khoa Karin Heeroma Yohji Itoh Gerardo Cornelio Pan-Chyr Yang | 2014 | Journal of Thoracic Oncology2014，，2： | 2 |
| 7 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma显示文摘 | MOK T S WU Y L THONGPRASERT S | 2009 | N Engl J Med2009，361，10： | 1 |
| 8 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma显示文摘 | Mok TS Wu YL Thongprasert S | 2009 | N Engl J Med2009，361，10： | 1 |
| 9 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)显示文摘 | Nick Thatcher Alex Chang Purvish Parikh José Rodrigues Pereira Tudor Ciuleanu Joachim von Pawel Sumitra Thongprasert Eng Huat Tan Kristine Pemberton Venice Archer Kevin Carroll | 2005 | The Lancet . 2005 (9496)2005，，9496： | 1 |
| 10 | Gefitinib or carboplat- in-paclitaxel in pulmonary adenocarcinoma显示文摘 | Mok TS Wu YL Thongprasert S | 2009 | N EnglJ Med2009，361，10： | 1 |
| 11 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma显示文摘 | Mok T S Wu Y L Thongprasert S | 2009 | N Engl J Med2009，361，10： | 1 |
| 12 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma显示文摘 | Mok TS Wu YL Thongprasert S | 2009 | N Engl J Med2009，361，10： | 1 |
| 13 | Biomarker analyses and final overall survival results from a phase Ⅲ,randomized, open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients'with advanced non-small- cell lung cancer in Asia (IPASS) 显示文摘 | Fukuoka M Wu YL Thongprasert S | 2011 | J Clin Oncol2011，29，21： | 1 |
| 14 | Gefitinib or Carboplatin - Paclitaxel in pulmonary adenocarcinoma 显示文摘 | Mok TS Wu YL Thongprasert S | 2009 | N Engl J Med2009，361，10： | 1 |
| 15 | Gefitinib or carboplatin- paelitaxel in pulmonaoT adenoearcinoma显示文摘 | Mok TS Wu YL Thongprasert S | 2009 | N Engl J Med2009，361，10： | 1 |
| 16 | Gefitinib or carbo- platin-paelitaxel in pulmonary adenocarcinoma显示文摘 | Mok TS Wu YL Thongprasert S | 2009 | N Engl J Med2009，361，1： | 1 |
| 17 | PhaseⅢtrial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer显示文摘 | Natale RB Thongprasert S Greco FA | 2011 | J Clin Oncol2011，29，8： | 1 |
| 18 | Phase m trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer 显示文摘 | Natale RB Thongprasert S Greco FA | 2011 | J Clin Oncol2011，29，8： | 1 |
| 19 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma显示文摘 | MOK TS WU YL THONGPRASERT S | 2009 | N EnglJ Med2009，361，10： | 1 |
| 20 | Gefitinib or carboplatin --paclitaxel in pulmonary adenocarcinoma显示文摘 | Mok T S Wu Y L Thongprasert S | 2009 | N Engl J Med2009，361，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员